BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 18838884)

  • 21. Prognostic value of serial [18F]fluorodeoxyglucose PET-CT uptake in stage III patients with non-small cell lung cancer treated by concurrent chemoradiotherapy.
    Zhang HQ; Yu JM; Meng X; Yue JB; Feng R; Ma L
    Eur J Radiol; 2011 Jan; 77(1):92-6. PubMed ID: 19695804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
    Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
    Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy.
    Tanaka H; Hayashi S; Hoshi H
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e113-7. PubMed ID: 24176011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Positron emission tomography/computed tomography and lymphovascular invasion predict recurrence in stage I lung cancers.
    Shiono S; Abiko M; Sato T
    J Thorac Oncol; 2011 Jan; 6(1):43-7. PubMed ID: 21079522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Repeat FDG-PET for predicting pathological tumor response and prognosis after neoadjuvant treatment in nonsmall cell lung cancer: comparison with computed tomography.
    Shiraishi K; Nomori H; Ohba Y; Kaji M; Mori T; Shibata H; Oya N; Sasaki J
    Ann Thorac Cardiovasc Surg; 2010 Dec; 16(6):394-400. PubMed ID: 21263419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer.
    Sasaki R; Komaki R; Macapinlac H; Erasmus J; Allen P; Forster K; Putnam JB; Herbst RS; Moran CA; Podoloff DA; Roth JA; Cox JD
    J Clin Oncol; 2005 Feb; 23(6):1136-43. PubMed ID: 15718309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
    Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project.
    Berghmans T; Dusart M; Paesmans M; Hossein-Foucher C; Buvat I; Castaigne C; Scherpereel A; Mascaux C; Moreau M; Roelandts M; Alard S; Meert AP; Patz EF; Lafitte JJ; Sculier JP;
    J Thorac Oncol; 2008 Jan; 3(1):6-12. PubMed ID: 18166834
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of FDG uptake in early stage non-small cell lung cancer.
    Hanin FX; Lonneux M; Cornet J; Noirhomme P; Coulon C; Distexhe J; Poncelet AJ
    Eur J Cardiothorac Surg; 2008 May; 33(5):819-23. PubMed ID: 18374589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic significance of the 18F-fluorodeoxyglucose positron emission tomography/computed tomography in early-stage nonsmall cell lung cancer.
    Geredeli C; Artac M; Kocak I; Koral L; Sakin A; Altinok T; Kaya B; Karaagac M
    J Cancer Res Ther; 2020; 16(4):816-821. PubMed ID: 32930124
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of circulating tumour cells with early relapse and 18F-fluorodeoxyglucose positron emission tomography uptake in resected non-small-cell lung cancers.
    Bayarri-Lara CI; de Miguel Pérez D; Cueto Ladrón de Guevara A; Rodriguez Fernández A; Puche JL; Sánchez-Palencia Ramos A; Ruiz Zafra J; Giraldo Ospina CF; Delgado-Rodríguez M; Expósito Ruiz M; Moyano Rodriguez MJ; Lorente JA; Serrano MJ
    Eur J Cardiothorac Surg; 2017 Jul; 52(1):55-62. PubMed ID: 28369376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial.
    Machtay M; Duan F; Siegel BA; Snyder BS; Gorelick JJ; Reddin JS; Munden R; Johnson DW; Wilf LH; DeNittis A; Sherwin N; Cho KH; Kim SK; Videtic G; Neumann DR; Komaki R; Macapinlac H; Bradley JD; Alavi A
    J Clin Oncol; 2013 Oct; 31(30):3823-30. PubMed ID: 24043740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Standard uptake value predicts survival in non-small cell lung cancer.
    Okereke IC; Gangadharan SP; Kent MS; Nicotera SP; Shen C; DeCamp MM
    Ann Thorac Surg; 2009 Sep; 88(3):911-5; discussion 915-6. PubMed ID: 19699919
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is post-treatment standardized uptake value a prognostic factor in unresectable non-small cell lung carcinoma?
    Yılmaz U; Yasar Z; Korkmaz E; Yalcın B; Koparal H; Ozbilek E
    Med Glas (Zenica); 2017 Aug; 14(2):204-210. PubMed ID: 28698535
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography as a predictor of response in locally advanced non-small-cell carcinoma of the lung.
    Roy S; Pathy S; Kumar R; Mohanti BK; Raina V; Jaiswal A; Taywade S; Garg K; Thulkar S; Mohan A; Mathur S; Behera D
    Nucl Med Commun; 2016 Feb; 37(2):129-38. PubMed ID: 26544097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
    Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
    Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
    Park SY; Cho A; Yu WS; Lee CY; Lee JG; Kim DJ; Chung KY
    J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The value of nodal information in predicting lung cancer relapse using 4DPET/4DCT.
    Li H; Becker N; Raman S; Chan TC; Bissonnette JP
    Med Phys; 2015 Aug; 42(8):4727-33. PubMed ID: 26233200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer.
    Goodgame B; Pillot GA; Yang Z; Shriki J; Meyers BF; Zoole J; Gao F; Dehdashti F; Patterson A; Siegel BA; Govindan R
    J Thorac Oncol; 2008 Feb; 3(2):130-4. PubMed ID: 18303432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.